Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microba Life SciencesASX:MAP Equity-to-Asset is 0.70 as of Dec. 2025, which is 8% below its 10-year median of 0.76. The stock has 6 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Microba Life Sciences ranks better than 67.14% on this metric.
The historical rank and industry rank for Microba Life Sciences's Equity-to-Asset or its related term are showing as below:
ASX:MAP'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.69 Med: 0.76 Max: 0.88
Current: 0.7
During the past 4 years, the highest Equity to Asset Ratio of Microba Life Sciences was 0.88. The lowest was 0.69. And the median was 0.76.
ASX:MAP's Equity-to-Asset is ranked better than 67.14% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.595
vs ASX:MAP: 0.70
Microba Life Sciences (ASX:MAP) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Microba Life Sciences Equity-to-Asset Related Terms
Microba Life Sciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Microba Life Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MAP vs TMO, DHR, IDXX: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Microba Life Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Microba Life Sciences's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microba Life Sciences (ASX:MAP) has a Equity-to-Asset of 0.70 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Microba Life Sciences and its competitors. This is near median its historical median of 0.76. Over the past decade, Microba Life Sciences' Equity-to-Asset has ranged from 0.69 to 0.88. According to the industry distribution chart, Microba Life Sciences ranks #69 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 32.9%.
Is Microba Life Sciences' Equity-to-Asset too high?
Microba Life Sciences' current Equity-to-Asset of 0.70 is near median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 0.88. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.60. Microba Life Sciences' value of 0.70 is 17.6% above this industry median. Based on the distribution chart, Microba Life Sciences ranks #69 out of 210 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Microba Life Sciences' Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #69 out of 210 companies for Equity-to-Asset. This puts Microba Life Sciences in the upper half of its industry. The industry median Equity-to-Asset is 0.60. Microba Life Sciences' value of 0.70 is 17.6% above this benchmark. Historically, Microba Life Sciences' own Equity-to-Asset has ranged from 0.69 to 0.88 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 0.60, Microba Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.60, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Microba Life Sciences's current Equity-to-Asset of 0.70 is 17.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Microba Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current Equity-to-Asset is 0.70, which is near median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.24, compared to a current price of A$0.06 — trading 76.3% below its estimated fair value. The current Equity-to-Asset is 0.70, which is near median its 10-year median of 0.76 and 17.6% above the Medical Diagnostics & Research industry median of 0.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Equity-to-Asset is 0.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MAP has been successfully added to your 
